openPR Logo
Press release

Pediatric Neuroblastoma Treatment Market Trends, Demand, and Insights 2024-2033

12-06-2024 11:48 AM CET | Health & Medicine

Press release from: The Business research company

Pediatric Neuroblastoma Treatment Market Trends

Pediatric Neuroblastoma Treatment Market Trends

"The Business Research Company recently released a comprehensive report on the Global Pediatric Neuroblastoma Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

According to The Business Research Company's, The pediatric neuroblastoma treatment market size has grown rapidly in recent years. It will grow from $1.67 billion in 2023 to $1.84 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to advancements in treatment modalities, increased awareness and early diagnosis, research and development initiatives, collaborative efforts, improved survival rates.

The pediatric neuroblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to emerging therapies, personalized medicine, global health initiatives, expanded access to treatment, patient advocacy and support. Major trends in the forecast period include collaborative research initiatives, gene therapy breakthroughs, novel drug development, early diagnosis and screening, patient advocacy and support.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/pediatric-neuroblastoma-treatment-global-market-report

Market Drivers and Trends:

The rising number of new cases of pediatric neuroblastoma is expected to propel the growth of the pediatric neuroblastoma treatment market going forward. The rising prevalence of neuroblastoma is increasing the demand for pediatric neuroblastoma treatment alternatives. As a result, pharmaceutical corporations and other stakeholders have boosted their investment in research and development, promoting innovation in the industry. Furthermore, the availability of new diagnostic technology and screening procedures has resulted in earlier neuroblastoma discovery, allowing for earlier treatments and better outcomes. For instance, in March 2023, according to an article published by the American Society of Clinical Oncology (ASCO), a US-based organization for oncology professionals and physicians, neuroblastoma affects approximately 700 to 800 youngsters in the United States each year. In the United States, neuroblastoma accounts for 6% of all childhood malignancies. Neuroblastoma affects around 90% of children under the age of five. Therefore, the rising number of new cases of pediatric neuroblastoma is driving the growth of the pediatric neuroblastoma treatment market.

Research and development are the key trend gaining popularity in the pediatric neuroblastoma treatment market. Major companies operating in the pediatric neuroblastoma treatment market are focusing on advance research and development to sustain their position in the market. For instance, in March 2021, Ascentage Pharma Group Inc., a US-based pharmaceutical company that develops novel cancer therapies, announced that the US Food and Drug Administration (FDA) had designated alrizomadlin (APG-115) as a rare pediatric disease (RPD) for the treatment of neuroblastoma. The FDASIA, which went into force in 2012, introduced the rare pediatric disease priority review voucher (PRV) program to reward sponsors for the discovery of innovative medicines for the treatment of rare pediatric disorders. Ascentage Pharma is developing alrizomadlin, an orally given, selective, small-molecule antagonist of the MDM2 protein. Alrizomadlin has a high affinity for MDM2 and is intended to stimulate p53's tumor suppressive activities by inhibiting the MDM2-p53 protein-protein connection.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=9924&type=smp

Major Key Players of the Market:

United Therapeutics Corporation; APEIRON Biologics AG; Baxter International Inc.; Cell Ectar Biosciences Inc.; Pfizer Inc.; MacroGenics Inc.; Bayer AG; Provectus Biopharmaceuticals Inc.; Sartorius AG; Y-mAbs Therapeutics Inc.; Amgen Inc.; Eli Lilly and Company; F. Hoffmann-La Roche AG; Clarity Pharmaceuticals; CureSearch for Children's Cancer; Novartis AG; LEO Pharma A/S; UCB SA; Johnson & Johnson Services Inc.; Abbott Laboratories; AbbVie Inc.; Merck & Co. Inc.; Sanofi SA; GlaxoSmithKline plc; Bristol-Myers Squibb Company; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; Boehringer Ingelheim International GmbH; Daiichi Sankyo Company Limited; Eisai Co. Ltd.

Pediatric Neuroblastoma Treatment Market 2024 Key Insights:

• The pediatric neuroblastoma treatment market will grow to $2.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%.
• Surging Pediatric Neuroblastoma Cases Propel Advancements In Treatment Market A Focus On Research, Innovation, And Early Detection
• Advancements In Pediatric Neuroblastoma Treatment Focus On Research And Development Initiatives By Leading Companies
• North America was the largest region in the pediatric neuroblastoma treatment market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=9924&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"""Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pediatric Neuroblastoma Treatment Market Trends, Demand, and Insights 2024-2033 here

News-ID: 3776154 • Views:

More Releases from The Business research company

Leading Companies Reinforce Their Presence in the Blanket Market
Leading Companies Reinforce Their Presence in the Blanket Market
The blanket market is steadily gaining traction as consumers increasingly seek comfort and style in their home essentials. With evolving preferences and technological advancements, this sector is set to experience consistent growth. Let's explore the current market value, key players, emerging trends, and the main segments fueling this expansion. Forecasted Blanket Market Size and Growth Trajectory The blanket market has seen consistent growth over recent years. From a market size
Global Trends Review: The Rapid Evolution of the Sporting and Athletic Goods Market
Global Trends Review: The Rapid Evolution of the Sporting and Athletic Goods Mar …
The sporting and athletic goods market is experiencing steady growth, driven by evolving consumer preferences and technological advancements. As health and wellness continue to gain importance globally, this market is set for notable expansion in the coming years. Let's explore the current market size, key factors fueling its growth, leading companies, major trends, and segmentation details. Forecast for Sporting and Athletic Goods Market Size Through 2029 The sporting and athletic
Train Seat Market Overview, Key Growth Factors, and Insights on Top Players
Train Seat Market Overview, Key Growth Factors, and Insights on Top Players
The train seat industry is experiencing notable growth, driven by advancements in technology and increasing demand for improved passenger comfort. As rail travel evolves, so does the need for innovative, efficient, and adaptable seating solutions that cater to modern requirements. Let's explore the current market status, key players, trends, and segments shaping the future of train seating. Train Seat Market Size and Growth Expectations The train seat market has seen
Leading Companies Solidifying Their Presence in the Spunbond Nonwovens Market
Leading Companies Solidifying Their Presence in the Spunbond Nonwovens Market
The spunbond nonwovens industry has been experiencing notable growth and shows promising prospects for the coming years. This expanding market is being driven by several innovations and increasing demand across diverse sectors, signaling a robust future. Projected Growth and Market Size of the Spunbond Nonwovens Market The spunbond nonwovens market has demonstrated solid expansion recently, with its size expected to rise from $15.57 billion in 2024 to $16.59 billion in

All 5 Releases


More Releases for Neuroblastoma

Pediatric Relapsed & Refractory Neuroblastoma Market Trades 2034
Market Overview The Pediatric Relapsed and Refractory Neuroblastoma Market is expanding as unmet needs remain high for children who fail first-line therapy or experience disease recurrence. Neuroblastoma, a rare pediatric cancer originating in nerve tissues, poses significant treatment challenges when it becomes resistant or relapses after conventional chemotherapy, surgery, and radiation. As a result, demand for novel immunotherapies, targeted biologics, CAR-T therapies, and precision medicine is accelerating globally. Improved survival outcomes,
Neuroblastoma Market Massive Growth opportunity Ahead
Neuroblastoma market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Neuroblastoma Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The
Pediatric Neuroblastoma Treatment Market - Redefining Possibilities: Advancement …
Newark, New Castle, USA: The "Pediatric Neuroblastoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Pediatric Neuroblastoma Treatment Market: https://www.growthplusreports.com/report/pediatric-neuroblastoma-treatment-market/7681 This latest report researches the industry structure,
Neuroblastoma Treatment Market Projected to Garner Significant Revenues by 2024
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants
Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market. Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under
04-14-2017 | Health & Medicine
TMR
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants